<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Qian Z</submitter><funding>Guangdong Basic and Applied Basic Research Foundation</funding><funding>National Natural Science Foundation of China</funding><funding>Natural Science Foundation of Guangdong Province of China</funding><funding>Science and Technology Projects in Guangzhou</funding><pagination>2474730</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11892071</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>57(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Previous studies have shown changes in gut microbiota after human immunodeficiency virus (HIV) infection, but there is limited research linking the gut microbiota of people living with HIV (PLWHIV) to metabolic diseases.&lt;h4>Methods&lt;/h4>A total of 103 PLWHIV were followed for 48 weeks of anti-retroviral therapy (ART), with demographic and clinical data collected. Gut microbiome analysis was conducted using metagenomic sequencing of fecal samples from 12 individuals. Nonalcoholic fatty liver disease (NAFLD) was diagnosed based on controlled attenuation parameter (CAP) values of 238 dB/m from liver fibro-scans. Participants were divided based on the presence of metabolic disorders, including NAFLD, overweight, and hyperlipidemia. &lt;i>Akkermansia&lt;/i> abundance in stool sample</pubmed_abstract><journal>Annals of medicine</journal><pubmed_title>Decreased intestinal abundance of &amp;lt;i&amp;gt;Akkermansia muciniphila&amp;lt;/i&amp;gt; is associated with metabolic disorders among people living with HIV.</pubmed_title><pmcid>PMC11892071</pmcid><funding_grant_id>2023A1515011587</funding_grant_id><funding_grant_id>KS0120220270]</funding_grant_id><funding_grant_id>81970012</funding_grant_id><funding_grant_id>2023A04J2398</funding_grant_id><pubmed_authors>Wu J</pubmed_authors><pubmed_authors>Qian Z</pubmed_authors><pubmed_authors>Cai S</pubmed_authors><pubmed_authors>Liao X</pubmed_authors><pubmed_authors>Xie J</pubmed_authors><pubmed_authors>Ou L</pubmed_authors><pubmed_authors>Zuo X</pubmed_authors><pubmed_authors>Zhong H</pubmed_authors><pubmed_authors>Chen S</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Peng J</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Decreased intestinal abundance of &amp;lt;i&amp;gt;Akkermansia muciniphila&amp;lt;/i&amp;gt; is associated with metabolic disorders among people living with HIV.</name><description>&lt;h4>Background&lt;/h4>Previous studies have shown changes in gut microbiota after human immunodeficiency virus (HIV) infection, but there is limited research linking the gut microbiota of people living with HIV (PLWHIV) to metabolic diseases.&lt;h4>Methods&lt;/h4>A total of 103 PLWHIV were followed for 48 weeks of anti-retroviral therapy (ART), with demographic and clinical data collected. Gut microbiome analysis was conducted using metagenomic sequencing of fecal samples from 12 individuals. Nonalcoholic fatty liver disease (NAFLD) was diagnosed based on controlled attenuation parameter (CAP) values of 238 dB/m from liver fibro-scans. Participants were divided based on the presence of metabolic disorders, including NAFLD, overweight, and hyperlipidemia. &lt;i>Akkermansia&lt;/i> abundance in stool sample</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-02T19:18:49.19Z</modification><creation>2025-04-04T02:51:06.556Z</creation></dates><accession>S-EPMC11892071</accession><cross_references><pubmed>40052450</pubmed><doi>10.1080/07853890.2025.2474730</doi></cross_references></HashMap>